[go: up one dir, main page]

MX2013013558A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013013558A
MX2013013558A MX2013013558A MX2013013558A MX2013013558A MX 2013013558 A MX2013013558 A MX 2013013558A MX 2013013558 A MX2013013558 A MX 2013013558A MX 2013013558 A MX2013013558 A MX 2013013558A MX 2013013558 A MX2013013558 A MX 2013013558A
Authority
MX
Mexico
Prior art keywords
composition
pharmaceutical composition
relates
formulated
preparing
Prior art date
Application number
MX2013013558A
Other languages
English (en)
Inventor
Jose Bernardo Iturraspe
Jose Castillo
Jose Lucio Nunez
Original Assignee
Capital Business Y Gestion De Finanzas S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP110101751 external-priority patent/AR081214A1/es
Priority claimed from ARP110103435 external-priority patent/AR083066A1/es
Application filed by Capital Business Y Gestion De Finanzas S L filed Critical Capital Business Y Gestion De Finanzas S L
Publication of MX2013013558A publication Critical patent/MX2013013558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica sólida que comprende fulvestrant sólido amorfo. Formulación de dicha composición en combinación con una composición solubilizante. El proceso de elaboración de dicha composición y un kit que la comprende.
MX2013013558A 2011-05-20 2012-04-23 Composicion farmaceutica. MX2013013558A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP110101751 AR081214A1 (es) 2011-05-20 2011-05-20 Composicion farmaceutica solida de solubilidad mejorada que comprende fulvestrant solido
ARP110103435 AR083066A1 (es) 2011-09-20 2011-09-20 Composicion farmaceutica
PCT/ES2012/070267 WO2012160223A1 (es) 2011-05-20 2012-04-23 Composicion farmaceutica

Publications (1)

Publication Number Publication Date
MX2013013558A true MX2013013558A (es) 2013-12-16

Family

ID=47216639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013558A MX2013013558A (es) 2011-05-20 2012-04-23 Composicion farmaceutica.

Country Status (7)

Country Link
US (2) US9029582B2 (es)
EP (1) EP2711010B1 (es)
BR (1) BR112013029758A2 (es)
CA (1) CA2836831C (es)
ES (1) ES2708302T3 (es)
MX (1) MX2013013558A (es)
WO (1) WO2012160223A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
GB0116620D0 (en) 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
SG165404A1 (en) * 2005-09-26 2010-10-28 Hospira Australia Pty Ltd Fulvestrant formulation
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations

Also Published As

Publication number Publication date
US9029582B2 (en) 2015-05-12
CA2836831A1 (en) 2012-11-29
CA2836831C (en) 2015-06-02
US20150202210A1 (en) 2015-07-23
EP2711010A4 (en) 2015-04-15
ES2708302T3 (es) 2019-04-09
EP2711010B1 (en) 2018-10-31
EP2711010A1 (en) 2014-03-26
BR112013029758A2 (pt) 2018-10-09
WO2012160223A1 (es) 2012-11-29
WO2012160223A9 (es) 2014-01-30
US20140088061A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
IL269804A (en) Conjugates of an active protein material and a method for their preparation
PH12014501108A1 (en) Anti-il-36r antibodies
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
PT2766380T (pt) Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
ZA201403803B (en) Composition,apparatus,kit and method and uses thereof
MX353579B (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
IL232936A0 (en) Antibody-drug conjugates and related compounds
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
GEP201706733B (en) Anti-il-23 antibodies
LT2841390T (lt) Stabilios formos geopolimero kompozicijos ir būdai
SG10201602218VA (en) Novel fuel compositions and methods for making same
EP3058370A4 (en) Methods and compositions for coronavirus diagnostics and therapeutics
WO2012121746A3 (en) Imaging beta cell mass
EP2473319A4 (en) COMPOSITION FOR A CUTTING WHEEL AND CUTTING WHEEL FROM THIS
IL228006B (en) Endodontic instruments, kits and methods for using endodontic instruments
MX2013013558A (es) Composicion farmaceutica.
MX2012013246A (es) Composicion supresora de polvo.
SG2014010433A (en) Stable compositions and methods for preparing the same
PL2688418T3 (pl) Bogata w stygmasterol kompozycja fitosterolowa i jej zastosowania
UA58018U (ru) Применение хондроитина сульфата для коррекции нарушений сперматогенеза у крыс
HK1197750A (en) Stable compositions and methods for preparing the same
TN2014000207A1 (en) Anti il-36r antibodies
AU2011900732A0 (en) Composition And Procedure For Enhancing Penis Size

Legal Events

Date Code Title Description
HH Correction or change in general